Fluocinolone Acetonide
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
- Fluocinolone Acetonide
- Fluocinolone Acetonide: From Topical Corticosteroid Use to Annular Atrophic Lichen Planus
Fluocinolone Acetonide: From Topical Corticosteroid Use to Annular Atrophic Lichen Planus
One-Sentence Summary
Fluocinolone acetonide is a topical glucocorticoid. Its original approved indications are not recorded in the supplied South African registration data. The TxGNN model predicts it may be useful for annular atrophic lichen planus. There are currently 0 clinical trials and 0 publications supporting this specific prediction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA registration record |
| Predicted New Indication | Annular atrophic lichen planus |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available for this drug. Fluocinolone acetonide is a topical glucocorticoid, and glucocorticoids have well-known anti-inflammatory and immunosuppressive effects. This reasoning comes from the drug class, not from the supplied data.
Lichen planus is a T-cell-mediated inflammatory skin disease, so suppressing the inflammatory infiltrate is a plausible way for a corticosteroid to help. The original indications are also missing from the registration record, so the similarity between old and new indications cannot be assessed.
TxGNN gave the same score (99.42%) to two related variants, hypertrophic lichen planus and lichen planus pigmentosus. The model therefore appears to be predicting a broad lichen planus signal, not a specific one for the annular atrophic form. Pigmentary and atrophic variants may respond differently from classic lichen planus, and this cannot be judged without direct evidence.
Clinical Trial Evidence
Currently no related clinical trials registered. No SANCTR, PACTR or ICTRP entries were supplied.
Literature Evidence
Currently no related literature available for annular atrophic lichen planus.
For reference, the fourth-ranked prediction, lichen planus pemphigoides (score 99.34%), has three indirect papers. None studies fluocinolone acetonide itself.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8065723 | 1994 | RCT | Oral Surg Oral Med Oral Pathol | Double-blind comparison of clobetasol propionate 0.05% and fluocinonide 0.05% in orabase for oral vesiculoerosive diseases |
| 6996618 | 1980 | Clinical study | Arch Dermatol | Topical fluocinonide in an adhesive base in 89 patients with oral erosive diseases including lichen planus. Study design not confirmed from the title. |
| 14620208 | 2003 | Review | Quintessence Int | Desquamative gingivitis as an early sign of mucocutaneous disease |
Fluocinonide and clobetasol are different molecules, so these results are class-level indirect evidence only.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 56/16.2/0942 | Otixal | Drops | Not stated in the registration record |
The route of administration for this product is not specified in the supplied data, so route compatibility with the predicted indication is still pending. Essential Medicines List (EML) status was not supplied.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
No drug interaction records were found in the queried database.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but it is the only support (L5). There are no trials or literature for this indication, and the drug’s original indications, mechanism and safety data are missing. The available product is registered only as “drops”, and its suitability for skin use is unconfirmed.
To proceed, the following is needed:
- SAHPRA package insert (PI) with approved indications, warnings and contraindications, which is a blocking gap for safety screening
- Mechanism-of-action data from DrugBank
- Confirmation of route and formulation compatibility with a dermatological or mucosal indication
- A literature and trial search for fluocinolone acetonide in lichen planus variants, including SANCTR and PACTR
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.